19021-35-3

Basic information

• Product Name: 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide
• Synonyms: 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide
• CAS NO: 19021-35-3
• Molecular Formula: C₈H₁₁ClN₂O₂S
• Molecular Weight: 234.71
• Mol File: 19021-35-3.mol

Chemical Properties

• Melting Point: 174-175℃
• Boiling Point: 372.3 °C at 760 mmHg
• Flash Point: 178.9 °C
• Appearance: /
• Density: 1.387 g/cm³
• Vapor Pressure: 9.73E-06mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide(19021-35-3)
• EPA Substance Registry System: 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide(19021-35-3)

Safety Data

• Hazardous Substances Data: 19021-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its presence in the structure allows for versatile chemical reactions, making it a valuable component in the development of new drugs.
Used in Dye and Pigment Manufacturing:
4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide is used in the manufacturing of dyes and pigments due to its chemical properties. Its versatility in chemical reactions contributes to the production of a wide range of colorants for various applications.
Used in Antibacterial Applications:
4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide has been studied for its potential antibacterial properties. It can be used as an active ingredient in the development of new antimicrobial agents to combat bacterial infections.
Used in Anti-inflammatory Applications:
4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide has also been studied for its potential anti-inflammatory properties. It can be utilized in the development of anti-inflammatory drugs to treat various inflammatory conditions.
However, it is important to handle 4-amino-3-chloro-N,N-dimethyl-benzenesulfonamide with caution, as it can be harmful if ingested or inhaled, and exposure to skin and eyes should be avoided.

InChI:InChI=1/C8H11ClN2O2S/c1-11(2)14(12,13)6-3-4-8(10)7(9)5-6/h3-5H,10H2,1-2H3

Upstream product

• 16761-18-5 4-acetamido-3-chlorobenzenesulphonyl chloride 
• 68252-74-4 N-(2-Chloro-4-dimethylsulfamoyl-phenyl)-acetamide 
• 124-40-3 dimethyl amine 

Downstream Products

• 84250-70-4 3-Chloro-4-formylamino-N,N-dimethyl-benzenesulfonamide 
• 1400284-71-0 tert-butyl 6-(2-chloro-4-(N,N-dimethylsulfamoyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 

Relevant articles and documents

PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS

The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as “PPA derivatives”), particularly 1H-pyrrolo[3,2-c]pyridine-6-amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I)

PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS

The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as "PPA derivatives"), particularly 1H-pyrrolo[3,2-c]pyridine-6- amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I)